Lantheus Holdings Share Price Today: Live Updates & Key Insights

Lantheus Holdings share price today is $76.17, up -2%. The stock opened at $77.95 against the previous close of $77.99, with an intraday high of $77.95 and low of $75.63.

Lantheus Holdings Share Price Chart

Lantheus Holdings

us-stock
To Invest in {{usstockname}}
us-stock

Lantheus Holdings Share Price Performance

$76.17 -0.02(-2%) LNTH at 23 Mar 2026 02:00 PM Drug Manufacturers - Specialty & Generic
Lowest Today 75.63
Highest Today 77.95
Today’s Open 77.95
Prev. Close 77.99
52 Week High 108.91
52 Week Low 47.25
Day’s Range: Low 75.63 High 77.95
52-Week Range: Low 47.25 High 108.91
1 day return -
1 Week return -2.66
1 month return +4.11
3 month return +12.25
6 month return +52.58
1 year return -23.13
3 year return -5.13
5 year return +273.01
10 year return -

Lantheus Holdings Institutional Holdings

BlackRock Inc 12.79

Vanguard Group Inc 10.37

HHG PLC 10.35

Farallon Capital Management, L.L.C. 8.40

FMR Inc 6.69

Morgan Stanley - Brokerage Accounts 6.00

State Street Corp 3.87

iShares Core S&P Mid-Cap ETF 3.32

Vanguard Total Stock Mkt Idx Inv 3.21

Geode Capital Management, LLC 2.67

iShares Russell 2000 ETF 2.52

JPMorgan Chase & Co 2.42

Reinhart Mahoney Capital Management Inc 2.42

Vanguard Small Cap Index 2.33

Dimensional Fund Advisors, Inc. 2.19

Swedbank AB 1.90

Avantis US Small Cap Value ETF 1.79

NORGES BANK 1.77

Janus Henderson Enterprise D 1.75

Janus Inst Mid Cap Growth CF 1.75

Carmignac Gestion 1.74

Carmignac Investissement A EUR Acc 1.64

Macquarie Group Ltd 1.61

Janus Henderson Triton D 1.42

Janus Henderson US SMID Cap Growth 1.42

Strategic Advisers Fidelity US TtlStk 1.40

Northern Trust Corp 1.31

Vanguard Small Cap Growth Index Inv 1.29

Deerfield Management Co 1.28

T. Rowe Price Associates, Inc. 1.26

American Century Companies Inc 1.19

Amvescap Plc. 1.13

Vanguard Institutional Extnd Mkt Idx Tr 1.11

Janus Henderson Contrarian D 1.10

Janus Henderson US Opportunistic Alpha 1.10

Fidelity Small Cap Discovery 1.05

Fidelity Small Cap Index 1.02

Fidelity Value 0.90

Nomura Small Cap Core I 0.90

Fidelity Series Small Cap Discovery 0.89

Lantheus Holdings Market Status

Strong Buy: 9

Buy: 3

Hold: 1

Sell: 0

Strong Sell: 0

Lantheus Holdings Fundamentals

Market Cap 5068.21 M

PB Ratio 4.531

PE Ratio 22.4135

Enterprise Value 5198.14 M

Total Assets 2227.40 M

Volume 1890429

Lantheus Holdings Company Financials

Annual Revenue FY24:1533910000 1533.9M, FY23:1205596000 1205.6M, FY22:935061000 935.1M, FY21:425208000 425.2M, FY20:339410000 339.4M

Annual Profit FY24:988291000 988.3M, FY23:646845000 646.8M, FY22:581703000 581.7M, FY21:187695000 187.7M, FY20:138761000 138.8M

Annual Net worth FY24:312442000 312.4M, FY23:104096000 104.1M, FY22:28067000 28.1M, FY21:-71279000 -71.3M, FY20:-13473000 -13.5M

Quarterly Revenue Q3/2025:384014000 384.0M, Q2/2025:378045000 378.0M, Q1/2025:372764000 372.8M, Q4/2024:391110000 391.1M, Q3/2024:378734000 378.7M

Quarterly Profit Q3/2025:222366000 222.4M, Q2/2025:241011000 241.0M, Q1/2025:237700000 237.7M, Q4/2024:248545000 248.5M, Q3/2024:242126000 242.1M

Quarterly Net worth Q3/2025:27771000 27.8M, Q2/2025:78755000 78.8M, Q1/2025:72945000 72.9M, Q4/2024:-11790000 -11.8M, Q3/2024:131093000 131.1M

About Lantheus Holdings & investment objective

Company Information Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Organisation Drug Manufacturers - Specialty & Generic

Employees 1193

Industry Drug Manufacturers - Specialty & Generic

CEO Ms. Mary Anne Heino

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Lantheus Holdings FAQs

What is the share price of Lantheus Holdings today?

The current share price of Lantheus Holdings is $76.17.

Can I buy Lantheus Holdings shares in India?

Yes, Indian investors can buy Lantheus Holdings shares by opening an international trading and demat account with Motilal Oswal.

How to buy Lantheus Holdings shares in India?

You can easily invest in Lantheus Holdings shares from India by:

Can I buy fractional shares of Lantheus Holdings?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Lantheus Holdings?

Lantheus Holdings has a market cap of $5068.21 M.

In which sector does Lantheus Holdings belong?

Lantheus Holdings operates in the Drug Manufacturers - Specialty & Generic sector.

What documents are required to invest in Lantheus Holdings stocks?

To invest, you typically need:

What is the PE and PB ratio of Lantheus Holdings?

The PE ratio of Lantheus Holdings is 22.41 and the PB ratio is 4.53.